Amneal Pharmaceuticals (AMRX) net assets (shareholders' equity)

Net assets · fiscal 2025
-$70.79M

Amneal Pharmaceuticals (AMRX) had net assets of -$70.79M at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$109.27M. Figures as of 19 Nov 2026, 11:31 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
-$70.79M
Highest on record
$504.75Mfiscal 2018
Lowest on record
-$109.27Mfiscal 2024
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Amneal Pharmaceuticals net assets (shareholders' equity), in more detail

Across the 8 fiscal years on record (2018–2025), the highest was $504.75M in fiscal 2018 and the lowest -$109.27M in fiscal 2024.

History · 8 fiscal years

Net assets by fiscal year

Amneal Pharmaceuticals net assets (shareholders' equity), year by year

Amneal Pharmaceuticals (AMRX) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025-$70.79M—
2024-$109.27M 652.4% down
2023$19.78M 93.4% down
2022$298.42M 17.2% down
2021$360.34M 18.8% up
2020$303.27M 30.7% up
2019$232.01M 54.0% down
2018$504.75M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Amneal Pharmaceuticals and comparable companies
CompanyNet assetsFiscal year
Cytokinetics CYTK-$659.63M2025
ABIVAX ABVX€455.21M2025
Bausch + Lomb BLCO$6.45B2025
Amneal Pharmaceuticals AMRX-$70.79M2025
Caris Life Sciences CAI$577.31M2025
Immunovant IMVT$852.59M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMRX

Amneal Pharmaceuticals, figure by figure

Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value

Amneal Pharmaceuticals net assets (shareholders' equity): questions and answers

What are Amneal Pharmaceuticals's net assets?

Amneal Pharmaceuticals (AMRX) had net assets of -$70.79M at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$109.27M.

What are the highest and lowest net assets figures on record for Amneal Pharmaceuticals?

Across the 8 fiscal years on record (2018–2025), the highest was $504.75M in fiscal 2018 and the lowest -$109.27M in fiscal 2024.

How is Amneal Pharmaceuticals's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Amneal Pharmaceuticals it is on record here for 8 fiscal years, 2018 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amneal Pharmaceuticals (AMRX) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/AMRX/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.